BiotechTube

IV Bisphosphonate q 4 weeks

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Conditions

Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Trial Timeline

Jan 1, 2005 → Mar 1, 2010

NCT ID
NCT00104650

About IV Bisphosphonate q 4 weeks

IV Bisphosphonate q 4 weeks is a phase 2 stage product being developed by Amgen for Bone Metastases in Men With Hormone-Refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00104650. Target conditions include Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

What happened to similar drugs?

10 of 20 similar drugs in Bone Metastases in Men With Hormone-Refractory Prostate Cancer were approved

Approved (10) Terminated (1) Active (9)
🔄Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
🔄Arzoxifene + PlaceboEli LillyPhase 3
🔄TanezumabEli LillyPhase 3
🔄Anastrozole + TamoxifenAstraZenecaPhase 3
🔄zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
🔄Zoledronic acidNovartisPhase 3
🔄Zoledronic acid + LetrozoleNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00104650Phase 2Completed

Competing Products

20 competing products in Bone Metastases in Men With Hormone-Refractory Prostate Cancer

See all competitors
ProductCompanyStageHype Score
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
EnzalutamideAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
MerestinibEli LillyPhase 1
21
FORTEO + PlaceboEli LillyPhase 1
29
Arzoxifene + PlaceboEli LillyPhase 3
40
TanezumabEli LillyPhase 3
40
Anastrozole + TamoxifenAstraZenecaPhase 3
40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
Zoledronic acid + LetrozoleNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
NilotinibNovartisPhase 1
29
Reclast (ZOL446, zoledronic acid)NovartisApproved
43
Zoledronic acidNovartisPhase 3
32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic AcidNovartisPhase 3
40
zoledronic acidNovartisPhase 1
29
Ruxolitinib continuous therapyNovartisPhase 2
39